SCHEMBL30507166

SCHEMBL30507166

CC(COc1ccc(S(C)(=O)=O)cc1)N1CCC2(CC1)C(=O)Nc1ccc(Cl)cc12

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.41
IP6K1 Q92551 8/20 0.40
IP6K3 Q96PC2 1/20 0.39
IP6K2 Q9UHH9 1/20 0.39
PGR P06401 4/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HTR1A P08908 2/20 0.36
HTR2A P28223 2/20 0.36
HTR7 P34969 2/20 0.36
HTR6 P50406 2/20 0.36
MET P08581 1/20 0.36
KCNH2 Q12809 1/20 0.35
SLC9A3 P48764 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25316319 1.00 SIGMAR1 (0.41) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL30506786 1.00 SIGMAR1 (0.41) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL25316061 1.00 SIGMAR1 (0.41) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL25315580 0.87 OPRM1 (0.42) HTR1AHTR2AHTR7HTR6
SCHEMBL25315584 0.87 OPRM1 (0.42) HTR1AHTR2AHTR7HTR6
SCHEMBL30507169 0.85 IP6K1 (0.38) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL30506736 0.85 IP6K1 (0.38) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL25319229 0.85 IP6K1 (0.38) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL25319232 0.85 IP6K1 (0.38) SIGMAR1IP6K1IP6K3IP6K2PGR
SCHEMBL26024806 0.85 IP6K1 (0.38) SIGMAR1IP6K1IP6K3IP6K2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 EP disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed